Array, Loxo to develop cancer drugs in potential $434M deal

Loxo Oncology and Array BioPharma agreed to co-develop the latter's preclinical drug candidate that targets an oncogenic activating mutation. The partners also agreed to collaborate in the discovery and development of small-molecule compounds against oncology targets chosen by Loxo. The deal entitles Array to as much $434 million in milestone fees plus sales royalties.

View Full Article in:

Daily Camera (Boulder, Colo.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA